Patents by Inventor Christopher D. Benjamin

Christopher D. Benjamin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vascular cell adhesion molecule (VCAM) polypeptides
    Patent number: 6252043
    Abstract: VCAM1 polypeptides and VCAM11/ICAM fusion proteins are disclosed.
    Type: Grant
    Filed: September 22, 1994
    Date of Patent: June 26, 2001
    Assignee: Biogen, Inc.
    Inventors: Catherine A. Hession, Roy R. Lobb, Susan E. Goelz, Laurelee Osborn, Christopher D. Benjamin, Margaret D. Rosa
  • Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
    Patent number: 5925351
    Abstract: This invention relates to compositions and methods comprising "lymphotoxin-.beta. receptor blocking agents", which block lymphotoxin-.beta. receptor signalling. Lymphotoxin-.beta. receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-.beta. receptor extracellular domain that act as lymphotoxin-.beta. receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-.beta. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-.beta. receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-.beta. receptor signalling is provided.
    Type: Grant
    Filed: July 21, 1995
    Date of Patent: July 20, 1999
    Assignee: Biogen, Inc.
    Inventors: Jeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
  • Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)
    Patent number: 5367056
    Abstract: DNA sequences encoding endothelial cell-leukocyte adhesion molecules ELAMs, methods for producing such molecules, and ELAMs (including the specific molecules ELAM1 and VLAM1 and 1b) essentially free of normally associated animal proteins are disclosed.DNA sequences encoding molecules involved in leukocyte adhesion (MILAs), methods for producing such molecules and MILAs (including the specific molecule, CDX) essentially free of normally associated animal proteins are also disclosed. Antibody preparations which are reactive for MILAs and also disclosed.Methods for identifying molecules which inhibit binding of leukocytes to endothelial cells, methods for inhibiting leukocyte binding to endothelial cells, and methods for detecting acute inflammation are disclosed.
    Type: Grant
    Filed: March 23, 1993
    Date of Patent: November 22, 1994
    Assignee: Biogen, Inc.
    Inventors: Catherine A. Hession, Roy R. Lobb, Susan E. Goelz, Laurelee Osborn, Christopher D. Benjamin, Margaret D. Rosa
  • DNA sequences encoding vascular cell adhesion molecules (VCAMS)
    Patent number: 5272263
    Abstract: DNA sequences encoding vascular cell adhesion molecules 1 and 1b ("VCAM1" and "VCAM1B"), recombinant DNA molecules comprising those sequences, and unicellular hosts transformed with those recombinant DNA molecules.
    Type: Grant
    Filed: December 18, 1989
    Date of Patent: December 21, 1993
    Assignee: Biogen, Inc.
    Inventors: Catherine A. Hession, Roy R. Lobb, Susan E. Goelz, Laurelee Osborn, Christopher D. Benjamin, Margaret D. Rosa